About Kate Therapeutics
Kate Therapeutics is a Healthcare company based in San Diego (United States) founded in 2020, and was acquired by Novartis in November 2024. It operates as an AAV-based gene therapies for muscle diseases are developed. Kate Therapeutics has raised $123.78 million across 4 funding rounds from investors including Novartis, University of Florida and Westlake BioPartners. The company has 46 employees. Its focus areas include Life Sciences, Gene Therapy, Diversified and Viral Vectors. Its legal entity is KATE THERAPEUTICS INC. Its competitors include Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and AskBio and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Kate Therapeutics was founded in 2020 and is headquartered in San Diego, United States. AAV-based gene therapies are developed by the company to target genetically defined muscle diseases within the biotechnology sector. Operations are concentrated on research and preclinical advancement of these therapies. Focus is maintained on addressing unmet needs in neuromuscular disorders through viral vector technologies.
- Headquarters San Diego, United States
- Employees 46
- Stage Acquired
- SectorsHealthcare
- Website katetherapeutics.com
- Social LinkedIn
- Acquired by Novartis (Nov 2024)
- Legal Name Kate Therapeutics Inc
Funding Insights of Kate Therapeutics
Kate Therapeutics has successfully raised a total of $123.78M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $21.78 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $123.78M
- Total Rounds 4
- Last Round Series A — $21.78M
- First Round $16M
(Feb 2021)
- Investors Count 4
All 4 funding rounds of Kate Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $21.78M | Series A | – | – | – |
| Jun 2023 | $51M | Series A | – | Westlake Village Biopartners, Versant Ventures | |
| Aug 2021 | $35M | Series A | – | – | – |
| Feb 2021 | $16M | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Kate Therapeutics
Kate Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, University of Florida and Westlake BioPartners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Westlake BioPartners is engaged in biotech venture capital investment. | – | westlakebio.com | Westlake Village, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
Early- to growth-stage startups are targeted for venture capital investments. | – | oup.vc | Bala Cynwyd, United States | |
Multiple courses and degrees are offered across diversified academic streams. | 1906 | ufl.edu | United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Kate Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kate Therapeutics
32 people are tracked at Kate Therapeutics (9 in leadership, 23 in team); the tracked headcount is 46.
| Name | Role | Group |
|---|---|---|
Mark Fielden | Senior VP Nonclinical, Co-founder | Leadership |
Sharif Tabebordbar | CSO & Co-founder | Leadership |
Christopher Kurtz | Chief Medical Officer | Leadership |
Beth Seidenberg | Director | Leadership |
Clare Ozawa | Director | Leadership |
Nathan Jones | Senior VP CMC Tech Ops | Leadership |
Rob Fiorentino | VP Clinical Development | Leadership |
Kevin Forrest | President and CEO | Leadership |
Laura Allen | Director, Human Resources | Leadership |
Aaron Berlin | Associate Scientist | Team |
Nandini Narayan | Senior Associate Scientist | Team |
Aislinn Puga | Executive Assistant | Team |
Nathan Wiley | Research Associate II | Team |
Natalie Johnston | Senior Research Associate | Team |
Harvir Grewal | CMC Upstream Scientist | Team |
Tamera Toland | Scientist II | Team |
Simon Ye | Scientist | Team |
Stephanie Landeros | Senior Research Associate | Team |
Jana Jenquin | Senior Scientist | Team |
Caroline Dang | Research Associate Ii-aav Capsid Engineering | Team |
12 more people are available in the full profile.
Complete people profiles for Kate Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kate Therapeutics
4 dated milestones of Kate Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Kate Therapeutics is founded.
- Funding First funding round of $16.0M.
- Funding Latest funding round, Series A, of $21.8M.
- Exit Acquired by Novartis.
Competitors of Kate Therapeutics
Kate Therapeutics has 10 listed competitors in our database, 8 of them funded. They include Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and AskBio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| cytokinetics.com | 1997 | San Francisco, United States | $60M | 423 | Muscle activators are developed for debilitating diseases. | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Kate Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Kate Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kate Therapeutics
Complete news archive for Kate Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kate Therapeutics
Kate Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Kate Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kate Therapeutics is a funded company, having raised a total of $123.78M across 4 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on Feb 2021.
Kate Therapeutics has 46 employees.
Kate Therapeutics was founded in 2020 and is headquartered in San Diego, United States. AAV-based gene therapies are developed by the company to target genetically defined muscle diseases within the biotechnology sector. Operations are concentrated on research and preclinical advancement of these therapies. Focus is maintained on addressing unmet needs in neuromuscular disorders through viral vector technologies.
Kate Therapeutics's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Kate Therapeutics has 5 investors. Key investors include Novartis, University of Florida, Westlake BioPartners, Versant Ventures, and Osage University Partners.
Kate Therapeutics operates through Kate Therapeutics Inc.
Yes. Kate Therapeutics was acquired by Novartis in November 2024.